Skip to main content
. 2013 Jan 1;9(1):136–143. doi: 10.4161/hv.22619

Table 2. Rates of general symptoms reported by study participants during days 0–6 after masked TIV vaccine or saline placebo injections, including vaccine-attributable rates (as rate difference).

Symptom Following Vaccine (%) Following Placebo (%) Rate Difference (95% CI) p value
Myalgia
 
 
 
 
 
 
 
 
Any
81/323
(25.1)
21/325
(6.5)
18.6% (13.2, 24.1)
< 0.001
 
Mild
67
(20.7)
18
(5.5)
15.2% (10.1, 20.2)
< 0.001
 
Moderate
11
(3.4)
3
(0.9)
2.5% (0.24, 4.7)
0.03
 
Severe
3
(0.9)
0
 
0.9% (-0.12, 2.0)
0.12
 
 
 
 
 
 
 
 
Tiredness
 
 
 
 
 
 
 
 
Any
66/323
(20.4)
34/325
(10.5)
10.0% (4.5, 15.5)
< 0.001
 
Mild
47
(14.6)
25
(7.7)
6.9% (2.0, 11.7)
0.006
 
Moderate
14
(4.3)
9
(2.8)
1.6% (-1.3, 4.4)
0.298
 
Severe
5
(1.5)
0
 
1.5% (0.2, 2.9)
0.03
 
 
 
 
 
 
 
 
Headache
 
 
 
 
 
 
 
 
Any
67/323
(20.7)
40/325
(12.3)
8.4% (2.7, 14.1)
0.004
 
Mild
55
(17.0)
31
(9.5)
7.5% (2.3, 12.7)
0.005
 
Moderate
10
(3.1)
9
(2.8)
0.3% (-2.3, 2.9)
0.821
 
Severe
2
(0.6)
0
 
0.6% (-0.2, 1.5)
0.248
 
 
 
 
 
 
 
 
Malaise/Feeling unwell
 
 
 
 
 
 
 
 
Any
36/323
(11.1)
21/325
(6.5)
4.7% (0.3, 9.0)
0.038
 
Mild
26
(8.1)
15
(4.6)
3.4% (-0.3, 7.2)
0.078
 
Moderate
7
(2.2)
5
(1.5)
0.6% (-1.5, 2.7)
0.577
 
Severe
3
(0.9)
1
(0.3)
0.6% (-0.6, 1.8)
0.372
 
 
 
 
 
 
 
 
Arthralgia
 
 
 
 
 
 
 
 
Any
22/323
(6.8)
9/325
(2.8)
4.0% (0.8, 7.3)
0.017
 
Mild
18
(5.6)
7
(2.2)
3.4% (0.5, 6.4)
0.026
 
Moderate
2
(0.6)
2
(0.6)
0.0% (-1.2, 1.2)
1
 
Severe
2
(0.6)
0
 
0.6% (-0.2, 1.5)
0.248
Sleep disturbance
 
25/323
(7.7)
12/325
(3.7)
4.0% (0.5, 7.6)
0.028
Diarrhea
 
19/323
(5.9)
6/325
(1.8)
4.0% (1.1, 7.0)
0.008
Fever
 
2/322
(0.6)
2/322
(0.6)
0 (-1.2, 1.2)
1
Nausea
 
10/323
(3.1)
6/325
(1.8)
1.3% (-1.1, 3.6)
0.325
Vomiting   2/323 (0.6) 1/325 (0.3) 0.3% (-0.7, 1.4) 0.623